Loading…

Medical Research Finder

Gut microbiota / Evidence-based microbiome knowledge (incl. AI chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

Immune Checkpoint Inhibitors (ICIs) & Primary mediastinal B-cell lymphoma (PMBCL)

Welcome to meRfi-GM!

Please register to continue your trial period!

meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

The development of Immune Checkpoint Inhibitors (ICIs) like pembrolizumab offers a promising therapeutic avenue for patients with Primary mediastinal B-cell lymphoma (PMBCL), particularly those with relapsed or refractory disease.

References:
Camus et al. 2021 Expert Review of Anticancer Therapy 21(9): 941-956

see also:
CD274 (Programmed death-ligand 1 (PD-L1)) & Primary mediastinal B-cell lymphoma (PMBCL)
[Pembrolizumab & Primary mediastinal B-cell lymphoma (PMBCL)](brain://AB67YBJxfU6B9KE6F7GBKw/PembrolizumabPrimaryMediastinalBcellL…

Pembrolizumab in the treatment of refractory primary mediastinal large B-cell lymphoma: safety and efficacy
Camus et al. 2021 Expert Review of Anticancer Therapy 21(9): 941-956

12/17/2025